New gene therapy combo aims to boost ovarian cancer survival

NCT ID NCT06915025

Recruiting now Disease control Sponsor: Imunon Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 7 times

Summary

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive either chemo alone or chemo plus IMNN-001. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMNN-001 (a gene therapy given into the abdomen)
What this could lead to: If it works, this could offer a new treatment option that extends survival for people with advanced ovarian cancer.
What could go wrong: This is a large phase 3 trial, but the added therapy may not improve outcomes over chemo alone and could cause more side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

Advent Health
RECRUITING

Orlando, Florida, 32804, United States
Erlanger Health
RECRUITING

Chattanooga, Tennessee, 37403, United States
Froedtert and The Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Masonic Cancer Center, University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
Providence Cancer Institute
RECRUITING

Portland, Oregon, 97213, United States
Providence Sacred Heart Medical Center & Children's Hospital
RECRUITING

Spokane, Washington, 99204, United States
Sanford Health
RECRUITING

Sioux Falls, South Dakota, 57104, United States
Washington University School of Medicine in St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.